<DOC>
	<DOC>NCT02515734</DOC>
	<brief_summary>This study is to verify the advantage of FOLFOXIRI plus cetuximab over FOLFOXIRI plus bevacizumab as the first-line therapy in metastatic colorectal cancer patients with RAS wild-type tumors.</brief_summary>
	<brief_title>A Study of FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab</brief_title>
	<detailed_description>This study is to verify the advantage of FOLFOXIRI plus cetuximab over FOLFOXIRI plus bevacizumab as the first-line therapy in metastatic colorectal cancer patients with RAS wild-type tumors. In this study the investigators employed deepness of response as a primary endpoint.</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Histologically confirmed colorectal cancer RAS wildtype Measurable lesion by RECIST (Ver.1.1) No past history of chemotherapy in the case of unresectable primary lesion/distant metastasis/lymph node metastasis.In the case of recurrence, no treatment for the first recurrence lesion after operation Eastern Cooperative Oncology Group (ECOG) Performance status 01.The case &gt;=71 years is PS0. Life expectancy of more than 6 months Patients have enough organ function for study treatment within 14 days before enrollment; 1. White blood cell (WBC)&gt;=3,000/mm3, &lt;12,000/mm3. 2. Neu&gt;=1,500/mm3. 3. Platelet count (PLT) &gt;=10.0x104/mm3. 4. Hb&gt;=9.0g/dL. 5. Total Bilirubin&lt;=1.5x Upper Limited Normal (ULN) 6. aspartate aminotransferase (AST) &lt;=2.5xULN. 7. alanine aminotransferase (ALT) &lt;=2.5xULN. 8. Creatinine&lt;=1.5xULN. 9. Proteinuria&lt;=1+. 10. prothrombin timeinternational normalized ratio (PTINR) &lt;=1.5 Must be able to swallow tablets Written informed consent Synchronous multiple malignancy or metachronous multiple malignancy within 5 years disease free interval Lynch syndrome Brain metastases Infectious disease Interstitial lung disease or pulmonary fibrosis Comorbidity or history of serious heart failure History of thromboembolic events Cerebrovascular disease History of hemoptysis/hematemesis Uncontrolled hypertension (systolic BP&gt;180mmHg, or diastolic BP&gt;100mmHg) Sensory alteration or paresthesia interfering with function Large quantity of pleural, abdominal or cardiac effusion Severe comorbidity (renal failure, liver failure, hypertension, etc) Prior radiotherapy for primary and metastases leision Men/women who are unwilling to avoid pregnancy Women who are pregnant or breastfeeding Women with a positive pregnancy test History of severe allergy HBsAg positive or active viral hepatitis Administration of blood products/ GranulocyteColony Stimulating Factor (GCSF), and blood transfusion within 14 days Surgical procedure or such as skinopen biopsy, trauma surgery, or other more intensive surgery within 28 days Systematic administration of antiplatelet drug or non steroid antiinflammatory drugs (NSAIDs) Diathesis of bleeding (history of hemoptysis, including cavitation and/or necrosis in lung metastasis confirmed by imaging), coagulopathy History of gastrointestinal perforation within 1 year Unhealed traumatic bone fracture Uncontrolled diarrhea History of organ recipient Prior cetuximab/bevacizumab/Irinotecan/Oxaliplatin treatment (Adjuvant therapy by Oxaliplatin is excluded) Administration of atazanavir sulfate Jaundice Ileus or bowel obstruction Clinical diagnosis of Alzheimer's Disease Insulin dependent diabetes Thyroid disease Any other cases who are regarded as inadequate for study enrollment by investigators</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>FOLFOXIRI</keyword>
	<keyword>Bmab</keyword>
	<keyword>Cmab</keyword>
</DOC>